Diego Ferrer-Pargada

Dr. Diego Ferrer-Pargada

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2021 in Clinical Microbiology and Infection
Verified
Journal Article
Closed access
JRJosé Ramón Blanco Ramos
José Ramón Blanco Ramos
MCMaria-Jesus Cobos-Ceballos
Maria-Jesus Cobos-Ceballos
FNFrancisco Navarro-Romero
Francisco Navarro-Romero
ISIsabel Sanjoaquin
Isabel Sanjoaquin
FRFrancisco Arnaiz de Las Revillas
Francisco Arnaiz de Las Revillas
JUJavier Ugedo
Javier Ugedo

1 July 2021 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
CACarlos Armiñanzas
Carlos Armiñanzas
FRFrancisco Arnaiz de Las Revillas
Francisco Arnaiz de Las Revillas
MCManuel Gutiérrez Cuadra
Manuel Gutiérrez Cuadra
AGAna Arnaiz Garcia
Ana Arnaiz Garcia
MSMarta Fernández Sampedro
Marta Fernández Sampedro
MFMaría Carmen Fariñas
María Carmen Fariñas
The aim of this study was to determine the usefulness of COVID-GRAM and CURB-65 scores as predictors of the severity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in Caucasian patients. This was a retrospective observational study including all adults with SARS-CoV-2 infection admitted to Hospital Universitario Marqués de Valdecilla from February to May 2020. Patients were stratified according to COVID-GRAM and CURB-65 scores as being at low–medium or high risk of critical illness. Univariate analysis, multivariate logistic regression models, receiver operating characteristic curve, and area under the curve (AUC) were calculated. A total of 523 patients were included (51.8% male, 48.2% female; mean age 65.63 years (standard deviation 17.89 years)), of whom 110 (21%) presented a critical illness (intensive care unit admission 10.3%, 30-day mortality 13.8%). According to the COVID-GRAM score, 122 (23.33%) patients were classified as high risk; 197 (37.7%) presented a CURB-65 score ≥2. A significantly greater proportion of patients with critical illness had a high COVID-GRAM score (64.5% vs 30.5%; P < 0.001). The COVID-GRAM score emerged as an independent predictor of critical illness (odds ratio 9.40, 95% confidence interval 5.51–16.04; P < 0.001), with an AUC of 0.779. A high COVID-GRAM score showed an AUC of 0.88 for the prediction of 30-day mortality, while a CURB-65 ≥2 showed an AUC of 0.83. The COVID-GRAM score may be a useful tool for evaluating the risk of critical illness in Caucasian patients with SARS-CoV-2 infection. The CURB-65 score could be considered as an alternative.

5 July 2022 in Pain Practice
Verified
Journal Article
Closed access
César Fernandez-de-las-PeñasCésar Fernandez-de-las-Peñas
César Fernandez-de-las-Peñas
PPPaula Parás‐Bravo
Paula Parás‐Bravo
DFDiego Ferrer-Pargada
Diego Ferrer-Pargada
ICIgnacio Cancela‐Cilleruelo
Ignacio Cancela‐Cilleruelo
JRJorge Rodríguez‐Jiménez
Jorge Rodríguez‐Jiménez
MHManuel Herrero-Montes
Manuel Herrero-Montes

7 July 2022 in Viruses
Verified
Journal Article
Open access
PDF file
César Fernandez-de-las-PeñasCésar Fernandez-de-las-Peñas
César Fernandez-de-las-Peñas
JVJuan Antonio Valera-Calero
Juan Antonio Valera-Calero
MHManuel Herrero-Montes
Manuel Herrero-Montes
PLPablo del Valle Loarte
Pablo del Valle Loarte
RRRafael Rodríguez-Rosado
Rafael Rodríguez-Rosado
Paula Parás-BravoPaula Parás-Bravo
Paula Parás-Bravo
This study aimed to analyze correlations between Self-Report Leeds Assessment of Neuropathic Symptoms (S-LANSS) and PainDETECT with proxies of sensitization, pain-related, or psychological/cognitive variables in coronavirus disease, 2019 (COVID-19) survivors exhibiting post-COVID pain. Demographic, clinical, psychological, cognitive, sensitization-associated symptoms, and health-related quality of life were collected in 146 survivors with post-COVID pain. The PainDETECT and S-LANSS questionnaires were used for assessing neuropathic pain-related symptoms. Patients were assessed with a mean of 18.8 (SD 1.8) months after hospitalization. Both questionnaires were positively associated with pain intensity (p < 0.05), anxiety (PainDETECT p < 0.05; S-LANSS p < 0.01), sensitization-associated symptoms (p < 0.01), catastrophism (p < 0.01), and kinesiophobia (p < 0.01) and negatively associated with quality of life (PainDETECT p < 0.05; S-LANSS p < 0.01). Depressive levels were associated with S-LANSS (p < 0.05) but not with PainDETECT. The stepwise regression analyses revealed that 47.2% of S-LANSS was explained by PainDETECT (44.6%), post-COVID pain symptoms duration (1.7%), and weight (1.1%), whereas 51.2% of PainDETECT was explained by S-LANSS (44.6%), sensitization-associated symptoms (5.4%), and anxiety levels (1.2%). A good convergent association between S-LANSS and PainDETECT was found. Additionally, S-LANSS was associated with symptom duration and weight whereas PainDETECT was associated with sensitization-associated symptoms and anxiety levels, suggesting that the two questionnaires evaluate different aspects of the neuropathic pain spectrum in post-COVID pain patients.

23 February 2023 in Diagnostics
Verified
Journal Article
Open access
PDF file
MHManuel Herrero-Montes
Manuel Herrero-Montes
César Fernandez-de-las-PeñasCésar Fernandez-de-las-Peñas
César Fernandez-de-las-Peñas
DFDiego Ferrer-Pargada
Diego Ferrer-Pargada
SISheila Izquierdo-Cuervo
Sheila Izquierdo-Cuervo
BABeatriz Abascal-Bolado
Beatriz Abascal-Bolado
Paula Parás-BravoPaula Parás-Bravo
Paula Parás-Bravo
Pain symptoms after the acute phase of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) are present in almost 50% of COVID-19 survivors. The presence of kinesiophobia is a risk factor which may promote and perpetuate pain. This study aimed to investigate variables associated with the presence of kinesiophobia in a sample of previously hospitalized COVID-19 survivors exhibiting post-COVID pain. An observational study was conducted in three urban hospitals in Spain, including one hundred and forty-six COVID-19 survivors with post-COVID pain. Demographic (age, weight, height), clinical (intensity and duration of pain), psychological (anxiety level, depressive level, sleep quality), cognitive (catastrophizing), sensitization-associated symptoms, and health-related quality of life variables were collected in 146 survivors with post-COVID pain, as well as whether they exhibited kinesiophobia. Stepwise multiple linear regression models were conducted to identify variables significantly associated with kinesiophobia. Patients were assessed a mean of 18.8 (SD 1.8) months after hospital discharge. Kinesiophobia levels were positively associated with anxiety levels (r: 0.356, p < 0.001), depression levels (r: 0.306, p < 0.001), sleep quality (r: 0.288, p < 0.001), catastrophism (r: 0.578, p < 0.001), and sensitization-associated symptoms (r: 0.450, p < 0.001). The stepwise regression analysis revealed that 38.1% of kinesiophobia variance was explained by catastrophism (r2 adj: 0.329, B = 0.416, t = 8.377, p < 0.001) and sensitization-associated symptoms (r2 adj: 0.381, B = 0.130, t = 3.585, p < 0.001). Kinesiophobia levels were associated with catastrophism and sensitization-associated symptoms in previously hospitalized COVID-19 survivors with post-COVID pain. Identification of patients at a higher risk of developing a higher level of kinesiophobia, associated with post-COVID pain symptoms, could lead to better therapeutic strategies.

16 May 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
DFDavid Iturbe Fernández
David Iturbe Fernández
VCVerónics Pulito Cueto
Verónics Pulito Cueto
VMVictor Manuel Mora-Cuesta
Victor Manuel Mora-Cuesta
SRSara Remuzgo-Martínez
Sara Remuzgo-Martínez
DFDiego Ferrer-Pargada
Diego Ferrer-Pargada
JCJosé Manuel Cifrián
José Manuel Cifrián
Osteopontin (OPN) is a glycoprotein involved in Th1 and Th17 differentiation, and inflammation and tissue remodeling. OPN is a biomarker of disease activity in patients with autoimmune inflammatory conditions. This study aimed to assess the diagnostic and prognostic value of OPN in interstitial lung diseases (ILDs). Between May 2016 and October 2019, 344 patients with ILD were recruited at the Hospital Universitario Marqués de Valdecilla (Spain) and were prospectively followed-up. This study involved the determination of OPN serum levels by ELISA and OPN RNA expression quantified using qPCR. Six genetic polymorphisms in OPN (rs28357094, rs2853749, rs2853750, rs11728697, rs7695531, and rs1126616) were genotyped using TaqMan assays. OPN serum levels were also assessed in 140 healthy controls. OPN serum levels (median [interquartile range]) were significantly higher in ILD patients than in controls (1.05 [0.75–1.51] ng/mL versus 0.81 [0.65–0.98] ng/mL in healthy controls; p < 0.01). OPN serum levels were inversely correlated with the forced vital capacity. OPN serum levels were also higher in ILD patients who died or underwent lung transplantation when compared with the remaining ILD patients (1.15 [0.80–1.72] ng/mL versus 0.99 [0.66–1.32] ng/mL; p = 0.05). Survival worsened in ILD patients with OPN > 1.03 ng/mL at 1, 3, and 5 years. No statistically significant differences in the genetic frequencies of OPN polymorphisms or the RNA expression were found among the different ILD groups. Elevated levels of OPN in the serum may be a useful indicator in identifying patients with ILD who are more likely to experience poor outcomes.